Table 1 Summary of IC₅₀ values for cisplatin-treated human cells.

Cell line	Treatment	Average IC₅₀	SEM	p-value
U2OS	DMSO	18.4	2.15	–
	10 µM KS15	25.6	2.01	0.811
	20 µM KS15	29.9	3.50	0.290
	50 µM KS15	41.9	4.11	0.001
	10 µM SR8278	25.1	3.19	0.864
	20 µM SR8178	25.8	3.75	0.781
	50 µM SR8178	37.1	6.11	0.014
	10 µM SR + 10 µM KS	33.3	3.72	0.082
	10 µM SR + 20 µM KS	35.5	3.99	0.031
	10 µM SR + 50 µM KS	40.8	3.72	0.002
	10 µM KS + 20 µM SR	36.7	5.29	0.018
	10 µM KS + 50 µM SR	41.3	4.94	0.001
HaCaT	DMSO	3.2	0.18	–
	10 µM KS15	4.9	0.56	0.711
	20 µM KS15	4.9	0.85	0.723
	50 µM KS15	6.0	1.21	0.237
	10 µM SR8278	4.5	0.49	0.865
	10 µM SR + 10 µM KS	5.8	1.07	0.306
	10 µM SR + 20 µM KS	6.6	1.44	0.118
	10 µM SR + 50 µM KS	7.4	1.34	0.042
A549	DMSO	9.4	1.55	–
	10 µM KS15	9.9	1.84	0.999
	20 µM KS15	12.5	1.06	0.661
	50 µM KS15	12.8	2.39	0.574
	10 µM SR8278	8.6	1.04	0.999
	10 µM SR + 10 µM KS	12.6	0.91	0.633
	10 µM SR + 20 µM KS	15.3	2.52	0.121
	10 µM SR + 50 µM KS	17.3	1.39	0.023

Non-linear regression was used to calculate IC₅₀ values for U2OS, HaCaT, and A549 cells treated with cisplatin and the indicated concentrations of KS15 and SR8278 as shown in Figs. 1 and 2. One-way ANOVAs were used to identify KS15 and SR8278 treatment conditions that significantly impacted IC₅₀ values in comparison to the vehicle (DMSO)-treated control.

Quick links

Search